International Isotopes shuffles management team
Following the retirement of chairman and treasurer Ira Lon Morgan, radiopharmaceutical manufacturer International Isotopes has made some additional changes to its senior management team (SCAN 12/15/99). The Denton, TX-based company, which is in
Following the retirement of chairman and treasurer Ira Lon Morgan, radiopharmaceutical manufacturer International Isotopes has made some additional changes to its senior management team (SCAN 12/15/99). The Denton, TX-based company, which is in the process of transitioning to fully commercial operations, announced that newly appointed CEO David Camp has taken on the additional responsibilities of president. Camp replaces former president Carl Seidel, who has left the company.
In addition, Bryce Drake has joined International Isotopes as director of support services. Drake takes over the position from George Butterworth, who has stepped into the new position of director of radioisotope production. Also new to the management team is Scott Colpitts, who has replaced Gaylord King as director of radiopharmaceutical manufacturing. King will continue to work closely with the firm.
In other company news, the Bureau of Radiation Control of the Texas Department of Health approved amendments to International Isotopes operational and development licenses that will allow the company to produce commercial quantities of radioisotopes for use in nuclear medicine procedures.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
